Clinicians know that most of their GLP-1 patients will eventually stop the medication, and without new habits the weight ...

Diet weight loss company Noom announced it is launching a new program dubbed the Noom Microdose GLP-1Rx Program, which will provide members with personalized microdoses of GLP-1 medication. The ...

Diet trends and weight loss programs offer a dizzying assortment of tips and tricks — with mixed outcomes. Some people try diet after diet, hoping to make something stick. Even the most successful ...

Add Yahoo as a preferred source to see more of our stories on Google. So you want to lose some weight. And you'd really, really like this to be the last time you have to lose those pounds. In other ...

Noom leverages Waltz Connect to intelligently route GLP-1 prescriptions to the optimal pharmacy, enabling a comprehensive weight loss experience for employees CHICAGO & NEW YORK--(BUSINESS ...

Oh, to be a celebrity-fame, fortune, and the ability to have personal trainers and nutritionists on speed dial when you want to lose a few pounds. So, Noom claims to be the "last weight-loss program ...

In two analyses, Noom members were modeled to gain less than 2% of bodyweight up to 12 months after stopping medication — ...

NEW YORK--(BUSINESS WIRE)--Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better and healthier lives, today announced a ...

At-home health testing platform Ash is expanding its partnership with weight-loss company Noom to bring Noom's Proactive Health Microdose GLP-1Rx Program to market. Noom's program, launched in August, ...

The digital health company Noom announced Thursday that it is expanding its weight-loss drug offerings to include pills, starting with metformin. Starting today the company is now offering a low-cost ...

Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149. Stream NBC 5 for free, 24/7, wherever you are. The ...